January 25, 2023
Read in 2 minutes
Source/Disclosure
Disclosure:
Kim reports subsidies from the Ministry of Health and Welfare and South Korea. Personal expenses from Seoul National University Hospital; royalties from his DZMED during the conduct of the study. Patents issued to DZMED and patents pending for devices, methods, and computer programs for self-diagnosis and treatment of benign paroxysmal positional vertigo. Owns his 25% (2,750,000 shares) of DZMED. See research for relevant financial disclosures of all other authors.
A web-based system for the diagnosis and treatment of recurrent benign paroxysmal positional vertigo has been shown to be effective. JAMA Neurology.
“Vertigo/dizziness is the third most common symptom prompting emergency department visits, accounting for 3.5% to 11% of all emergency department visits and an estimated annual cost in the US of $3.9 million in 2011. It is done.” Dr. Hyo Jung Kim, Written by Seoul National University Bundang Hospital, and colleagues.
A web-based system for the diagnosis and treatment of recurrent benign paroxysmal positional vertigo was shown to be effective. Source: Adobe Stock
According to Kim and colleagues, benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo, found in approximately 17% to 42% of vertigo patients. BBPV is thought to be caused by dislodgement of otoliths that enter the semicircular canals, researchers report.
Brass repositioning procedures (CRM) can effectively treat BPPV, leading to immediate resolution in 80% of patients, with repeats increasing to 92%, write Kim and colleagues.
A previous study by Kim and colleagues found that a six-question questionnaire could diagnose associated canal and BPPV types with 71.2% accuracy. Of the six questions, the first three screened him for BPPV, and the next three he determined his BPPV subtype based on a more severe vertigo-inducing positioning maneuver, the study said. person writes.
Kim and colleagues conducted a randomized, controlled, parallel-group, double-blind study to determine the effectiveness of a web-based program. Of his 728 patients diagnosed with and treated for BPPV, 585 were enrolled. The patient was monitored for at least 2 years.
Of the 585 patients, 292 were randomized to treatment groups (mean age 60.3 years, 64% female) for CRM self-administration based on the questionnaire and subtype of BPPV identified in the questionnaire. I have received the video clip. Her 293 patients in the control group (mean age 61.1 years, 71% female) received only CRM video clips based on her BPPV type diagnosed at enrollment.
Overall, 128 patients (21.9%) relapsed (58 in the treatment group vs. 70 in the control group) and 109 patients (85.2%) successfully used the web-based system.
In an intention-to-treat analysis, 42 of 58 (72.4%) participants in the treatment group and 30 (42.9%) of 70 participants in the control group reported resolution of dizziness (95% CI, 0.13-0.46). ).
“This trial demonstrated the efficacy of a web-guided self-treatment system for recurrent BPPV,” write Kim and colleagues. “Use of this system may play an important role in telemedicine for vestibular disorders.”
